Significant Options Trading on Friday: PRAX, NPO, MCD
Enpro Inc Options Trading: Enpro Inc (NPO) experienced a trading volume of 809 options contracts, equating to about 80,900 underlying shares, with significant activity in the $220 strike call option expiring December 19, 2025.
McDonald's Corp Options Trading: McDonald's Corp (MCD) saw a higher trading volume of 13,790 options contracts, representing approximately 1.4 million underlying shares, with notable interest in the $315 strike call option expiring December 05, 2025.
Comparison of Trading Volumes: The options trading volumes for both NPO and MCD represent 44.8% and 41.9% of their respective average daily trading volumes over the past month.
Further Information: For additional details on available expirations for options on NPO, MCD, or PRAX, users can visit StockOptionsChannel.com.
Get Free Real-Time Notifications for Any Stock
Analyst Views on PRAX
About PRAX
About the author

Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy
- Leadership Change: Praxis Precision Medicines has appointed renowned neurologist Dr. Orrin Devinsky as the Head of Clinical Strategy, a move that signifies a strategic deepening in the neuroscience field and is expected to accelerate the commercialization of its late-stage product portfolio.
- Industry Influence: With over four decades of experience in epilepsy and clinical neuroscience, Devinsky has led pivotal clinical trials that have driven the development of transformative therapies, bringing invaluable expertise and industry influence to Praxis.
- Scientific Contributions: Devinsky's extensive background includes over 500 peer-reviewed publications and 16 patents in epilepsy therapeutics and drug delivery, enhancing Praxis's strength in scientific research and clinical development, positioning the company to stand out in a competitive market.
- Strategic Vision: Devinsky expressed that Praxis's scientific rigor and commitment to patients set it apart in the industry, and his involvement will help guide the company's innovations in epilepsy treatment, advancing new therapies aimed at improving patient quality of life.

Praxis Grants 434 Restricted Stock Units to Attract New Employees
- Employee Incentive Program: On January 2, 2026, Praxis granted 434 restricted stock units to three new non-executive employees under the 2024 Inducement Plan, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Equity Incentive Structure: These restricted stock units will vest in four equal annual installments, contingent upon the employee's continued employment with Praxis on each vesting date, thereby ensuring long-term commitment aligned with the company's growth.
- Talent Acquisition Strategy: The plan is exclusively designed to attract individuals who were not previously employed by Praxis, reflecting the company's proactive stance in talent competition and aiming to enhance its R&D capabilities in CNS disorder treatments.
- Business Development Potential: By implementing such equity incentives, Praxis not only attracts high-quality talent but also enhances its market competitiveness in the rapidly evolving biopharmaceutical industry, driving future innovation and growth for the company.








